Lineage Cell Therapeutics, Inc.(LCTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,661 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in LCTX
Events flagged as statistical outliers against LCTX's own multi-year baseline — not fixed dollar thresholds.
LCTX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Lineage Cell Therapeutics, Inc. (LCTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LCTX at 25.4/100 on a 32-signal composite quality model, placing it at rank #2,661 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (2.7) and free cash flow (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Lineage Cell Therapeutics, Inc. reports quarterly revenue of $1.1M, net income of $1.5M, free cash flow of $-7.4M. Top institutional holders of LCTX by reported 13-F value include BROADWOOD CAPITAL, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LCTX trades on the NYSE exchange and files with the SEC under CIK 876343. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LCTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lineage Cell Therapeutics, Inc. directly from SEC EDGAR. Lineage Cell Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 29 since 2024, currently 25.4 — an improving long-term trajectory across 55 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.1M
Net Income
Q2 2026
$1.5M
Free Cash Flow
Q2 2026
$-7.4M
ROIC
Q2 2026
-58.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+53.2% YoYNet Income
-241.4% YoYOperating Income
-70.5% YoYEPS (Diluted)
-211.1% YoYTotal Assets
-0.6% YoYOp. Cash Flow
+18.1% YoYFree Cash Flow
+17.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $14.6M +53.2% | $9.5M +6.2% | $8.9M -39.2% | $14.7M +238.7% | $4.3M +137.7% | $1.8M |
| Net Income | $-63.5M -241.4% | $-18.6M +13.4% | $-21.5M +18.2% | $-26.3M +38.9% | $-43.0M -108.3% | $-20.6M |
| Operating Income | $-36.6M -70.5% | $-21.5M +13.2% | $-24.7M -9.8% | $-22.5M +54.2% | $-49.2M -86.1% | $-26.4M |
| EPS (Diluted) | $-0.28 -211.1% | $-0.09 +25.0% | $-0.12 +20.0% | $-0.15 | — | — |
| Total Assets | $112.6M -0.6% | $113.2M +12.1% | $101.0M -18.3% | $123.7M -29.2% | $174.5M +61.7% | $107.9M |
| Operating Cash Flow | $-18.9M +18.1% | $-23.1M +19.2% | $-28.6M -2797.5% | $1.1M +104.5% | $-23.6M -19.3% | $-19.8M |
| Free Cash Flow | $-19.4M +17.8% | $-23.7M +19.1% | $-29.2M -4626.3% | $646.0K +102.7% | $-23.9M -20.6% | $-19.8M |
Get alerted when LCTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Lineage Cell Therapeutics, Inc. including:
Top Institutional Holders of LCTX
BROADWOOD CAPITAL INC
$64.9M49,560,992 shBlackRock, Inc.
$17.3M13,186,895 shVANGUARD CAPITAL MANAGEMENT LLC
$11.9M9,054,918 shDefender Capital, LLC.
$8.6M6,598,899 shGEODE CAPITAL MANAGEMENT, LLC
$6.9M5,299,457 shFIFTH THIRD BANCORP
$6.0M4,600,000 shMILLENNIUM MANAGEMENT LLC
$4.0M3,018,567 shSTATE STREET CORP
$3.0M2,314,180 shVANGUARD FIDUCIARY TRUST CO
$2.2M1,668,629 shNORTHERN TRUST CORP
$2.2M1,656,651 sh
| Fund | Value | Shares |
|---|---|---|
| BROADWOOD CAPITAL INC | $64.9M | 49,560,992 |
| BlackRock, Inc. | $17.3M | 13,186,895 |
| VANGUARD CAPITAL MANAGEMENT LLC | $11.9M | 9,054,918 |
| Defender Capital, LLC. | $8.6M | 6,598,899 |
| GEODE CAPITAL MANAGEMENT, LLC | $6.9M | 5,299,457 |
| FIFTH THIRD BANCORP | $6.0M | 4,600,000 |
| MILLENNIUM MANAGEMENT LLC | $4.0M | 3,018,567 |
| STATE STREET CORP | $3.0M | 2,314,180 |
| VANGUARD FIDUCIARY TRUST CO | $2.2M | 1,668,629 |
| NORTHERN TRUST CORP | $2.2M | 1,656,651 |
Companies Similar to LCTX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
AbCellera Biologics Inc.
Neuronetics, Inc.
ARS Pharmaceuticals, Inc.
STAAR SURGICAL CO
SANGAMO THERAPEUTICS, INC
Apyx Medical Corp
Foghorn Therapeutics Inc.
Coherus Oncology, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put LCTX on your watchlist
Track score changes the day Lineage Cell Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LCTX a good stock to buy?
13F Pro's AI-powered analysis of Lineage Cell Therapeutics, Inc. (LCTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LCTX are available on the LCTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LCTX is classified as a small company.
Which hedge funds own LCTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LCTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lineage Cell Therapeutics, Inc.'s investment landscape.